Physician profile
Daniel Rosen
NPI 1013173996
$6,709.88
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,830 · 2020: $340 · 2021: $908 · 2022: $257 · 2023: $345 · 2024: $30.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,189.36 | 2019 | |
| W. L. Gore & Associates, INC. | $1,085.39 | 2019-2023 | Gore Synecor Biomaterial |
| Intra-Sana Laboratories | $361.72 | 2022-2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Covidien LP | $259.60 | 2019 | |
| Medtronic, INC. | $222.78 | 2021-2023 | Signia |
| Boston Scientific Corporation | $191.89 | 2020-2021 | |
| Reshape Lifesciences INC. | $133.87 | 2021 | |
| Novo Nordisk INC | $87.09 | 2020 | |
| Amarin Pharma, INC. | $38.81 | 2022-2023 | |
| Olympus America INC. | $37.07 | 2019 | |
| Becton, Dickinson and Company | $27.49 | 2023 | Phasix Mesh |
| Currax Pharmaceuticals LLC | $16.05 | 2024 | Contrave |
| Tela Bio, INC. | $16.03 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Tolmar Pharmaceuticals, INC. | $14.94 | 2020 | |
| Glaxosmithkline, LLC. | $14.23 | 2024 | Trelegy Ellipta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.